Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 16, 2001

View Archived Issues

Cubist meets primary endpoint in second phase III Cidecin trial

Hollis-Eden cleared to begin HE-2000 trial for hepatitis B

Japanese launch for Quidel's influenza test

Flamel signs drug delivery licensing agreement with Merck & Co.

Companies collaborate to develop inhalable small-molecule compounds

Research collaboration established by Sunesis and Chiesi

Deltagen and Hyseq collaborate on development of biotechnology drug candidates

Development of human monoclonal antibodies against enterovirus pursued by Genetastix and DCB

Human pharmacokinetics of oral carnosine reported at ASA meeting

New propofol formulation avoids hypertriglyceridemia of marketed preparation

Rigel's two lead product candidates subject of presentation at NYC conference

Peripherally mediated antiinflammatory and analgesic effects demonstrated for selective CB2 agonist

Oncophage enters fast track development

Amylin reaffirms plan to commence phase III AC-2993 program before end of year

Dapsone development for acne and burn itch progresses at Atrix

Small molecules selectively recognize human ER genetic variants according to ASBMR presentation

Speedel reports promising data from aliskiren study in hypertension

Calcium supplement associated with marked decrease in incidence of osteoporosis-related fractures

Biochemical studies with etoricoxib in man consistent with GI-sparing antiinflammatory profile

ML-3000 spares gastric mucosa in aspirin-treated rats

Agent for preventing preterm delivery to be filed in Japan

CP-4632 claimed as treatment for reperfusion injury

New anti-HIV agents emerge from R&D at Bristol-Myers Squibb

Schering-Plough presents potent and selective M2 and/or M4 antagonists

Japanese pharmaceutical company identifies peptides inhibiting PSA activity

Adenosine analogues from CV Therapeutics and potential uses

Inhibitors of MMPs designed at Advanced Syntech

Heterocyclic amines as adenosine receptor modulators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...